Agenda

*topics subject to change prior to date of event

7:30 am CHECK-IN / BREAKFAST
8:00 am WELCOME AND INTRODUCTIONS
Elias Anaissie, M.D., Medical Director CTI Clinical Trial & Consulting; Program Director
8:10 am AML and ALL: STATE OF THE ART IN 2022
Hagop M. Kantarjian, M.D.
8:40 am CML, MDS, MPNs: STATE OF THE ART IN 2022
Hagop M. Kantarjian, M.D.
9:10 am BREAK / VIRTUAL & LIVE EXHIBITOR HALL
9:25 am UPDATE ON NOVEL THERAPIES FOR HODGKIN LYMPHOMA AND AGGRESSIVE NON-HODGKIN LYMPHOMA
TBD
9:55 am SEQUENCING THERAPY OPTIONS FOR PATIENTS WITH INDOLENT NHL AND CLL/SLL
TBD
10:25 am IMMUNOTHERAPIES FOR HEMATOLOGIC MALIGNANCIES
Nina Shah, M.D.
11:30 am LUNCH
12:30 pm MULTIPLE MYELOMA (MM): STATE OF THE ART IN 2022
Sagar Lonial, M.D.
1:00 pm AL-AMYLOIDOSIS, WALDENSTROM MACROGLOBULINEMIA (WM): STATE OF THE ART IN 2022
Sagar Lonial, M.D.
1:30 pm CLOSING
James Essell, M.D., Medical Director Cincinnati Cancer and Cellular Therapy Cancer Center, Program Co-Director